Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent Cushing’s Syndrome Expected by End of 2024 Management Hosting …
ANDOVER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a technology company, specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, is …
FREMONT, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. UBS Genomic Medicine Summit in …
Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2-Associated Arrhythmogenic Right …
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and …
REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2024. Recent …
AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), the mobile experience platform that guides your customers through every step of their journey with you, announces its financial results for the …
─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin ─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain …
Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024 Evalstotug (CAB-CTLA-4 antibody) demonstrated a …
SANTA CLARA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor and electronics ecosystem, today announced financial results for its second quarter ended …
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the …
Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical Collaboration for ECO Synthesis™ Manufacturing Platform …
– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as Chief Financial Officer – – Conference call today at 5:00 …
CHICAGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) today announced its second quarter 2024 results. Business Highlights Net sales of $560.8 million Realized LME aluminum price of $2,288/MT in second quarter is up $98/MT from …
22 additional new franchise shop commitments in the second quarter 9 shop openings year-to-date through August 8th CHICAGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Potbelly Corporation (NASDAQ: PBPB), (“Potbelly” or the “Company”) the iconic neighborhood …
Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for 4D-150 in a broad wet age-related macular degeneration (wet AMD) population, which includes patients representative of the planned Phase 3 study …
Q4’24 Financial Results and Recent Business Highlights Revenue of $247.4 million GAAP gross margin of 45.8 percent Non-GAAP gross margin of 53.4 percent GAAP diluted earnings per share of $5.22 Non-GAAP diluted earnings per share of $0.64 SAN JOSE, Calif …
- Grew Q2 2024 Revenue 3%, System-wide Sales 8% and System-wide Comp Sales 2% vs. Q2 2023 - - Increased Clinic Count to 960 at June 30, 2024 - SCOTTSDALE, Ariz., Aug. 08, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager …
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …
SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of …
05 days 19:48:49
